United Therapeutics Q2 2023: revenue $596.5M (+28%), net income $259.2M (+123%)

UNITED THERAPEUTICS Corp

2023-Q2 EPS reported $10.08 revenue$1,103,400,000

Total revenues $596.5M (+28% YoY), net income $259.2M (+123%), diluted EPS $5.24.
Tyvaso (including DPI) sales $318.9M, up 59% YoY, driven by patient growth and inventory build.
Orenitram sales $95.1M (+20%); Remodulin sales $127.2M (-4% YoY).
CEO expects $4B annual revenue run rate by mid-decade with continued expansion.
Share-based comp expense fell 79% to $13.8M due to stock price performance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UNITED THERAPEUTICS Corp reported the quarter ended June 30, 2023 results: revenue $596.5 million, net income $259.2 million, EPS $5.24 per diluted share. Guidance reaffirmed.

Period: the quarter ended June 30, 2023
Revenue: $596.5 million
Net income: $259.2 million
EPS: $5.24 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001082554-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.